Yasushi Goto

A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study

Plain Language SummaryWhat is this summary about?This is a summary of the publication about the HERTHENA-Lung01 study, which was published in the Journal of Clinical Oncology in September 2023. The study included 277 adults with non-small-cell lung cancer (NSCLC) that had a mutat...

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

In advanced non-squamous non-small cell lung cancer (non-sq NSCLC), companion diagnostic testing (CDx) identifies actionable driver alterations and guides initial targeted therapy. However, disease progression inevitably occurs through acquired resistance, including activation of...